<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211206053305N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-10</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the Effect of Two Different Methods of Anesthesia on Pain and Nausea and Vomiting in Children with Cancer</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation and Comparison of the Effectiveness of General Anesthesia with Souffleran and Propofol on Nausea, Vomiting and Agitation after Bone Marrow Aspiration and Intrathecal Injection in Children with Cancer Referred to Bahrami Hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63998</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done using limited randomization method of block randomization type. The size of all the blocks is equal and in this two-group trial, the participants are assigned equally to two intervention and control groups of 15 people using blocks of 6. The randomization tool will be a random sequence generation software. In order to hide random allocation, non-transparent sealed envelopes with random sequence will be used. Each of the random sequences created is recorded on a card and the cards are placed in the envelopes in order. In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order.Finally, the lids of the envelopes are glued and placed in a box. At the time of the registration of the participants, according to the order of entry of the eligible participants into the study, one of the envelopes will be opened and the assigned group of that participant will be revealed. The person who created the random sequence will not be involved in other stages of the study, including the allocation of participants, Blinding description: Blinding of the Type of Intervention Performed in Patients Will Be Done in the Data Collection Stage (lack of knowledge of the Examiner about the Intervention Group) and the Stage of Data Analysis (lack of knowledge of the Statistical Analyst of the Type of Intervention in Each Group). Therefore, the forthcoming Study will be in the form of Triple Blind .In this Way, the Patients are Children and their Parents Do Not know about the Study Group and do not know Which Group they are in. On the other hand, the Person who Collects the Information and Registers it in the Patient Information Sheet does not know the Patient Group, and on the third hand, the Person who Analyzes the Information also does not know the Patient Group because the Patients are Divided into 2 Groups: 1 and 2 and do not know the Name of the Group.</study_design>
      <phase>3</phase>
      <hc_freetext>Agitation and Nausea and Vomiting.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: Patients in the First Group will Receive 35 mg / kg Fentanyl Before Induction of Anesthesia. In the Next Step, They will be Induced Anesthesia by Receiving 8% Souffluran. Continuation of anesthesia is with isoflurane inhalation gas. Intervention 2: Intervention Group: Patients in the Second Group will Receive 35 mg / kg Fentanyl Before Induction of Anesthesia. In the Next Step, by Receiving Propofol at a Dose of 2 mg / kg, They will be Induced Under Anesthesia. Continuation of Anesthesia is with Isoflurane Inhalation Gas.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyedeh Mahsa Hosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No3,Yas Dead end, Tavanir Blvd , Valiasr Street , Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1434874983</zip>
        <telephone>+98 11 5216 1764</telephone>
        <email>Smahsahosseini1376@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bita Malekianzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 3 , Yas dead end , Tavanir Ave , Valiasr Ave , Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1434874983</zip>
        <telephone>+98 912 957 7267</telephone>
        <email>bmalekianzadeh@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All Children Between the Ages of 1 and 10 Have a Diagnosis of Cancer that Requires General Anesthesia for Intrathecal Injection and Bone Marrow Biopsy</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>10 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Dissatisfaction of the Patient or her/his legal Guardian to Participate in the Study
Lack of Proper Cooperation of the Patient or his/her legal Guardian
History of Any Past or Present lung Disease or Involvement
History of Past or Present Respiratory Distress
History of Any Past or Present Cardiovascular Disease
Simultaneous Involvement of Any Disorders leading to Nausea and Vomiting
History of Any Drug Allergies, Allergies to Eggs, Soy
History of Convulsion</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: Patients in the First Group will Receive 35 mg / kg Fentanyl Before Induction of Anesthesia. In the Next Step, They will be Induced Anesthesia by Receiving 8% Souffluran. Continuation of anesthesia is with isoflurane inhalation gas.</i_keyword>
      <i_keyword>Intervention Group: Patients in the Second Group will Receive 35 mg / kg Fentanyl Before Induction of Anesthesia. In the Next Step, by Receiving Propofol at a Dose of 2 mg / kg, They will be Induced Under Anesthesia. Continuation of Anesthesia is with Isoflurane Inhalation Gas.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of Nausea and Vomiting. Timepoint: Post Operative Nausea and Vomiting will be Measured After Transferring Patients to the Recovery Room. Method of measurement: Examination.</prim_outcome>
      <prim_outcome>Agitation. Timepoint: Pediatric Anesthesia Emergence Delirium Score will be Measured  after Transferring Patients to the Recovery Room. Method of measurement: Pediatric Anesthesia Emergence Delirium Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-23</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>No 3, Yas dead end , Tavanir Ave , Valiasr Ave , Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
